Aclarion CEO to Present at 2024 Maxim Healthcare Virtual Summit

Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced that CEO Brent Ness will present at the 2024 Maxim Healthcare Virtual Summit on October 15, 2024. The presentation, scheduled for 2:00 p.m. ET, will be part of a series hosted by Maxim Group LLC senior analysts featuring biotechnology, diagnostic, medical device, and healthcare information technology companies.

The company's Nociscan platform represents a significant advancement in noninvasive diagnostic technology for chronic low back pain, a condition affecting millions worldwide and contributing substantially to healthcare costs and lost productivity. By utilizing Magnetic Resonance Spectroscopy data processed through proprietary algorithms, Nociscan helps distinguish between painful and nonpainful discs in the lumbar spine, providing physicians with critical insights to optimize treatment strategies.

This presentation opportunity at a major healthcare investment summit underscores the growing recognition of AI-driven diagnostic solutions in modern medicine. The ability to accurately identify pain sources through noninvasive means could revolutionize treatment approaches for chronic back pain, potentially reducing unnecessary surgeries and improving patient outcomes. The healthcare technology sector continues to attract significant investment interest as innovations like Nociscan demonstrate potential to address longstanding clinical challenges.

The summit's focus on interactive discussions with CEOs and key management highlights the importance of leadership in driving healthcare innovation forward. For more information about Aclarion's technology, visit https://www.aclarion.com. The company's participation in such events demonstrates the increasing integration of advanced technology solutions in traditional healthcare practices, signaling a shift toward more data-driven and precise diagnostic approaches in pain management and treatment optimization.